And as the curtain rises on these initial negotiations, the drama is set to continue with the subsequent negotiation phases slated for 2027 to 2029.
Financial Figures and Future Implications
The financial implications are enormous. Consider this: Eliquis alone drained nearly $16.5 billion from the government’s coffers between June 2022 and May 2023. Jardiance followed with a hefty $7 billion tag.
For drug companies not willing to join the dance, the penalty looms large, akin to a formidable tax specter.
And as this plays out, the political divide deepens. House Republicans, for instance, voice concerns about escalating care costs for seniors and potential setbacks in medical advancements.
First 10 Drugs For Negotiations : Voices of Dissent
Neil Bradley of the U.S. Chamber of Commerce, which is entangled in its lawsuit against the program, added to the criticism, hinting that the Biden administration might have been hasty and overlooked potential negotiation pitfalls.
